Profile data is unavailable for this security.
About the company
Ocean Biomedical Holdings, Inc., formerly Ocean Biomedical, Inc., is a United States-based biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. In oncology, it is developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). In fibrosis, it is developing a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS). It has three product candidates: a malaria vaccine candidate targeting either or both of Plasmodium falciparum schizont egress antigen (PfSEA-1), and parasite antigen Plasmodium falciparum glutamic-acid-rich protein(PfGARP); a humanized mAb malaria therapeutic candidate targeting PfGARP; and a small molecule malaria therapeutic candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-98.59m
- Incorporated2021
- Employees9.00
- LocationOcean Biomedical Inc55 Claverick Street, Room 212PROVIDENCE 02903United StatesUSA
- Phone+1 (401) 444-7375
- Fax+1 (302) 655-5049
- Websitehttps://www.oceanbiomedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 58.49m | 8.00 | -- | 0.7199 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
Calcimedica Inc | 0.00 | -14.94m | 58.53m | 14.00 | -- | 3.39 | -- | -- | -2.64 | -2.64 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -48.34 | -63.99 | -66.59 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
Carisma Therapeutics Inc | 15.07m | -81.22m | 58.58m | 107.00 | -- | 5.38 | -- | 3.89 | -2.01 | -2.01 | 0.3723 | 0.2623 | 0.1311 | -- | -- | 140,869.20 | -70.64 | -30.87 | -83.17 | -34.47 | -- | -- | -538.81 | -255.66 | -- | -- | 0.1717 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
Global Pharmatech Inc. | 3.18m | -2.24m | 59.28m | 217.00 | -- | 0.4376 | -- | 18.65 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 59.64m | 2.00 | -- | 9.19 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
Aeon Biopharma Inc | 0.00 | -137.01m | 59.86m | 10.00 | -- | -- | -- | -- | -3.68 | -3.68 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.14 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
Bakhu Holdings Corp | 0.00 | -1.92m | 60.26m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 60.98m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
Earth Science Tech Inc | 5.98m | 330.94k | 61.08m | 8.00 | 202.08 | 28.30 | 115.41 | 10.21 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
Kronos Bio Inc | 7.59m | -116.39m | 61.30m | 61.00 | -- | 0.4475 | -- | 8.08 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
Turnstone Biologics Corp | 0.00 | -74.92m | 61.52m | 82.00 | -- | 0.7689 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 61.82m | 134.00 | 5.22 | 0.2473 | 1.89 | 0.24 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
Avrobio Inc | 0.00 | 30.31m | 62.40m | 13.00 | 2.01 | 0.7022 | 2.04 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Protara Therapeutics Inc | 0.00 | -42.47m | 63.62m | 26.00 | -- | 0.6049 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
Holder | Shares | % Held |
---|---|---|
Polar Asset Management Partners, Inc.as of 31 Mar 2024 | 2.69m | 7.76% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 432.79k | 1.25% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 259.96k | 0.75% |
OMERS Administration Corp.as of 31 Mar 2024 | 245.40k | 0.71% |
Geode Capital Management LLCas of 31 Mar 2024 | 233.45k | 0.67% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 136.31k | 0.39% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 80.76k | 0.23% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 63.03k | 0.18% |
Cohen & Company Financial Management LLCas of 30 Sep 2023 | 59.72k | 0.17% |
AllianceBernstein LPas of 31 Mar 2024 | 55.08k | 0.16% |